Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 12;102(19):e33711.
doi: 10.1097/MD.0000000000033711.

Proton pump inhibitor use and the risk for Parkinson's disease: A nationwide population-based study in Taiwan

Huan-Lin Chen  1   2 , Wei-Yi Lei  3 , Jen-Hung Wang  4 , Ming-Jong Bair  1   2 , Chien-Lin Chen  3   5
Affiliations

Proton pump inhibitor use and the risk for Parkinson's disease: A nationwide population-based study in Taiwan

Huan-Lin Chen et al. Medicine (Baltimore). .

Abstract

Previous studies have shown that proton pump inhibitors (PPIs) are associated with an increased risk of dementia. However, little is known about the relationship between PPIs use and Parkinson's disease (PD). This study aimed to examine whether PPI use was associated with an increased risk of developing clinically verified PD. This used data from the Taiwan National Health Insurance Research Database for the period between 1999 and 2011, and patients with PPI use were compared with 1 to 1 propensity score-matched controls by age, sex, cohort entry year, and comorbidity. A multivariate analysis was performed using Cox proportional hazards models to estimate the association between PPI use and PD risk. Subgroup analyses according to sex, age, and comorbidities were also conducted. In total, 56,785 PPI users and 56,785 matched controls were enrolled in this study. In the PPI cohort, 366 patients developed PD during a median follow-up of 5.0 years. The incidence rate of PD was 1.48-fold higher in PPI users than in non-PPI users (90.0 vs 133.2 per 100,000 person-years), with an adjusted hazard ratio of 1.76 (95% confidence interval, 1.48-2.08). In the subgroup analysis, the adjusted risk of PD in the PPI and non-PPI cohorts increased in the subgroups regardless of age, sex, and comorbidities. The results of this retrospective, nationwide, population-based cohort study in Taiwan indicate that PPI use is associated with the risk of PD development. Further mechanistic studies on the effect of PPI on PD are needed.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Flowchart of subjects enrolled into the study.
Figure 2.
Figure 2.
Kaplan–Meier curves showing a significant difference in cumulative incidence of PPI user among patients with PD and controls. PD = Parkinson’s disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tolosa E, Gaig C, Santamaria J, et al. . Diagnosis and the premotor phase of Parkinson disease. Neurology. 2009;72:S12–20. - PubMed
    1. Schwab RS. Symptomatology and medical treatment of Parkinson’s disease. Int J Neurol. 1961;2:61–75. - PubMed
    1. Strang RR. The association of gastro-duodenal ulceration and Parkinson’s disease. Med J Aust. 1965;1:842–3. - PubMed
    1. Tanner CM, Ottman R, Goldman SM, et al. . Parkinson disease in twins: an etiologic study. JAMA. 1999;281:341–6. - PubMed
    1. Werneck AL, Alvarenga H. Genetics, drugs and environmental factors in Parkinson’s disease. A case-control study. Arq Neuropsiquiatr. 1999;57:347–55. - PubMed

Substances

-